Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ACB
ACB logo

ACB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.459
Open
3.430
VWAP
3.42
Vol
601.56K
Mkt Cap
193.38M
Low
3.380
Amount
2.06M
EV/EBITDA(TTM)
--
Total Shares
56.71M
EV
290.55M
EV/OCF(TTM)
--
P/S(TTM)
0.71
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
Show More

Events Timeline

(ET)
2026-04-23
13:10:00
Roth Capital: Cannabis Products Rescheduled to Schedule 3
select
2026-04-23
10:30:00
Trump Orders Medical Marijuana Products to Schedule III
select
2026-04-23
10:00:00
Trump Signs Order to Reschedule Medical Marijuana to Schedule III
select
link
2026-04-22 (ET)
2026-04-22
12:00:00
Trump Administration Expected to Reclassify Cannabis on Wednesday
select
link
2026-03-19 (ET)
2026-03-19
11:20:00
Representative Proposes Bill to Protect Legal Cannabis Businesses
select
link
2026-03-09 (ET)
2026-03-09
08:50:00
Significant Increases in Indicative Borrow Rates for Liquid Options
select
2026-03-05 (ET)
2026-03-05
08:50:00
Klarna Group Borrow Rate Increases to 31.14%
select
2026-02-27 (ET)
2026-02-27
08:50:00
Latest Data Shows Gemini Space Station Borrow Rate Increases to 40.17%
select
2026-02-25 (ET)
2026-02-25
08:50:00
Largest Indicative Borrow Rate Increases Among Liquid Option Names
select

News

stocktwits
2.0
05-01stocktwits
AKAN Stock Soars 300%, Set for Best Week Ever
  • Stock Surge: AKAN's stock has surged 300% this week, marking its best weekly performance ever, reflecting improved investor sentiment across cannabis stocks, particularly after the U.S. Justice Department moved state-regulated marijuana to Schedule III, significantly boosting optimism in the sector.
  • Micro Float Advantage: With a public float of only 534,420 shares following multiple reverse stock splits, AKAN's stock skyrocketed 1,700% in April, outperforming peers like Trulieve and Canopy Growth, highlighting the sensitivity of micro-float stocks to buying pressure during market rebounds.
  • Strategic Shift: AKAN is increasingly focusing on the Canadian and European markets while building a telecommunications infrastructure through its First Towers & Fiber unit in Mexico, which is expected to generate $2 million in contracted cash flow over the next decade, providing a hedge against the volatility typical in pure cannabis companies.
  • Market Sentiment High: Retail sentiment for AKAN on Stocktwits is extremely bullish, with message volumes surging 231,800% over the past month, indicating strong investor interest in the stock, despite potential short-term corrections, as traders remain optimistic about its future performance.
CNBC
5.0
05-01CNBC
Autonomous Trucks Face Significant Challenges Despite AI Advances
  • Limited Technological Impact: Despite ongoing advancements in AI, Inceptio Technology's CEO Julian Ma states that these improvements have minimal effect on the timeline for commercializing autonomous trucks, with full commercialization expected by mid-2028, highlighting the complexities of industry development.
  • Data Accumulation Goals: Inceptio aims to collect 5 billion kilometers of driving data by the end of 2028 to support fully autonomous heavy-duty trucks, emphasizing the critical role of data in autonomous driving and the necessity for partnerships and regulatory approval to achieve this goal.
  • Industry-Leading Mileage: Inceptio has recorded over 700 million kilometers of autonomous driving, significantly surpassing competitors like Pony.ai, which has logged 4.2 million kilometers, establishing a strong foundation for future technology validation and market penetration.
  • Increasing Regulatory Challenges: Chinese authorities have suspended new autonomous driving licenses due to safety incidents, reflecting the regulatory risks faced by the rapidly expanding industry and underscoring the close relationship between technology and policy.
stocktwits
2.0
04-30stocktwits
AKAN Stock Surges Following Marijuana Reclassification
  • Stock Performance: Since the marijuana reclassification, AKAN stock has significantly outperformed peers Tilray, Canopy Growth, and Aurora Cannabis, which have seen declines of 8%, 4%, and 8% respectively, while AKAN surged 32%.
  • Market Reaction: In the latest pre-market trading, AKAN shares surged 32%, marking its fourth-largest single-day gain this year, reflecting strong market confidence in its future growth potential.
  • Policy Impact: The U.S. Department of Justice's reclassification of medical marijuana as a less dangerous drug is expected to ease regulatory burdens on licensed operators, provide tax relief, and support research, driving AKAN's strong performance.
  • Retail Trader Sentiment: Over the past 30 days, message volume for AKAN on Stocktwits has skyrocketed by over 106,200%, indicating extremely bullish sentiment among retail investors, with many predicting the stock could reach triple digits.
seekingalpha
8.0
04-24seekingalpha
U.S. Marijuana Reclassification Impact Limited as Stocks Retreat
  • Market Reaction: On Thursday, cannabis stocks retreated after early gains as investors reassessed the limited impact of the U.S. government's move to reclassify FDA-approved and state-licensed marijuana, with Cronos Group (CRON), Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), and OrganiGram Holdings (OGI) seeing declines between 7% and 14%.
  • Policy Details: Acting Attorney General Todd Blanche announced on social media that FDA-approved marijuana and state-licensed marijuana would be rescheduled from Schedule I to Schedule III, although this measure applies specifically to certain FDA-approved products rather than the broader market, resulting in uneven benefits across the sector.
  • Industry Response: FundCanna CEO Adam Stettner noted that medical operators could benefit from clearer federal alignment and potential tax relief, while companies focused on adult-use markets continue to face existing restrictions, including limited access to capital and regulatory fragmentation.
  • Market Expectations: Todd Harrison, founding partner at CB1 Capital Management, indicated that while the rescheduling of medical cannabis takes effect immediately, the hearing for adult use is set for June, failing to meet investors' higher expectations and leading to a more pessimistic market sentiment.
stocktwits
8.5
04-24stocktwits
U.S. Places Medical Cannabis Products in Schedule III
  • Policy Impact: The U.S. government's decision to place FDA-approved marijuana products and state-licensed medical cannabis programs into Schedule III is expected to facilitate clinical research and broaden treatment access, thereby enhancing the legitimacy of medical cannabis in modern healthcare.
  • Tilray's Expansion Plans: Tilray is exploring participation in a federal pilot program run by the Center for Medicare and Medicaid Innovation, aiming to supply hemp-derived medical cannabis through cancer clinics, which is intended to improve services for underserved patients.
  • Market Reaction Volatility: Although Tilray's stock surged by 19% following the policy announcement, it ultimately closed down 12%, reflecting investor concerns over the limited scope of the order, which also negatively impacted other cannabis companies' stock prices.
  • Optimistic Industry Outlook: Roth Capital Partners views the partial rescheduling order as “extremely favorable,” potentially alleviating Section 280E tax restrictions, improving import and export prospects, and paving the way for eventual adult-use rescheduling, thus enhancing overall sector investability.
stocktwits
8.0
04-23stocktwits
DOJ Updates Marijuana Classification Policy
  • Policy Change Context: The U.S. Department of Justice has formally proposed reclassifying state-licensed medical marijuana from Schedule I to Schedule III, which, while not legalizing marijuana, reduces regulatory hurdles and offers tax relief for licensed operators, expected to enhance medical research and expand access to treatments.
  • Market Reaction: Following the announcement, shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma (IGC) fell between 2-5% in morning trading despite previous gains, indicating a cautious market response to the policy change.
  • Investor Sentiment: Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish’ with message volumes surging, reflecting optimistic expectations for the cannabis industry's revival, with some users claiming Tilray will become the “king of the U.S. cannabis market.”
  • Akanda Corp. Outperformance: In contrast to major cannabis stocks, Akanda Corp. (AKAN) saw a 6% increase, extending a remarkable 215% surge from the previous session, with investors debating whether this explosive rally is driven by optimism over cannabis reclassification or the stock's low float.
Wall Street analysts forecast ACB stock price to rise
3 Analyst Rating
Wall Street analysts forecast ACB stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
6.28
Averages
6.77
High
7.39
Current: 0.000
sliders
Low
6.28
Averages
6.77
High
7.39
Canaccord
Buy
downgrade
$10 -> $9
AI Analysis
2026-02-05
Reason
Canaccord
Price Target
$10 -> $9
AI Analysis
2026-02-05
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Aurora Cannabis to C$9 from C$10 and keeps a Buy rating on the shares.
Canaccord
Buy
initiated
$10
2026-01-27
Reason
Canaccord
Price Target
$10
2026-01-27
initiated
Buy
Reason
Canaccord initiated coverage of Aurora Cannabis with a Buy rating and C$10 price target. The medical-first operator is "the leading medical player" in Canada and "a foremost player" in the key international markets of Germany, Poland, Australia, and the UK, the analyst tells investors in a note starting coverage of the the Canadian cannabis group. A domestic pivot supported an expansion into the high-margin international markets, where gross margins are roughly 2.5-times higher, on average, than in Aurora's medically focused Canadian business, the analyst noted.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ACB
Unlock Now

Valuation Metrics

The current forward P/E ratio for Aurora Cannabis Inc (ACB.O) is 19.16, compared to its 5-year average forward P/E of -53.72. For a more detailed relative valuation and DCF analysis to assess Aurora Cannabis Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-53.72
Current PE
19.16
Overvalued PE
299.43
Undervalued PE
-406.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.99
Current EV/EBITDA
7.67
Overvalued EV/EBITDA
39.78
Undervalued EV/EBITDA
-47.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.36
Current PS
0.63
Overvalued PS
4.65
Undervalued PS
0.07

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

how is cannibis securities doing today
Intellectia · 8 candidates
Market Cap: >= 100.00MPrice: >= $1.00Themes: The Cannabis IndustryMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
CGC logo
CGC
Canopy Growth Corp
511.04M
TLRY logo
TLRY
Tilray Brands Inc
803.02M
SNDL logo
SNDL
SNDL Inc
391.39M
VFF logo
VFF
Village Farms International Inc
328.97M
ACB logo
ACB
Aurora Cannabis Inc
201.89M
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.49B
Should I Buy cannabis stocks?
Intellectia · 9 candidates
Market Cap: >= 50.00MThemes: The Cannabis IndustryList Exchange: XNYS, XNASMonthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
what cannabis stocks would you buy?
Intellectia · 4 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryQuarter Revenue Yoy Growth: >= 0.0%Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
SNDL logo
SNDL
SNDL Inc
386.25M
ACB logo
ACB
Aurora Cannabis Inc
204.15M
cannabis
Intellectia · 8 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryIs Optionable: TrueMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
marijuana stocks
Intellectia · 8 candidates
Market Cap: >= 200.00MRegion: US, CanadaPrice: >= $1.00Themes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M
Top cannabis stocks to buy
Intellectia · 9 candidates
Market Cap: >= 50.00MRevenue Ttm: >= 10.00MThemes: The Cannabis Industry
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M

Whales Holding ACB

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Aurora Cannabis Inc (ACB) stock price today?

The current price of ACB is 3.41 USD — it has decreased -0.58

What is Aurora Cannabis Inc (ACB)'s business?

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.

What is the price predicton of ACB Stock?

Wall Street analysts forecast ACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is6.77 USD with a low forecast of 6.28 USD and a high forecast of 7.39 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Aurora Cannabis Inc (ACB)'s revenue for the last quarter?

Aurora Cannabis Inc revenue for the last quarter amounts to 94.19M USD, increased 6.79

What is Aurora Cannabis Inc (ACB)'s earnings per share (EPS) for the last quarter?

Aurora Cannabis Inc. EPS for the last quarter amounts to 0.03 USD, decreased -94.23

How many employees does Aurora Cannabis Inc (ACB). have?

Aurora Cannabis Inc (ACB) has 1101 emplpoyees as of May 09 2026.

What is Aurora Cannabis Inc (ACB) market cap?

Today ACB has the market capitalization of 193.38M USD.